Amedisys Stock Analysis

AMED Stock  USD 92.89  0.39  0.42%   
Amedisys is undervalued with Real Value of 101.89 and Target Price of 96.86. The main objective of Amedisys stock analysis is to determine its intrinsic value, which is an estimate of what Amedisys is worth, separate from its market price. There are two main types of Amedisys' stock analysis: fundamental analysis and technical analysis.
The Amedisys stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and Amedisys' ongoing operational relationships across important fundamental and technical indicators.
  
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Amedisys. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income.
For information on how to trade Amedisys Stock refer to our How to Trade Amedisys Stock guide.

Amedisys Stock Analysis Notes

About 91.0% of the company shares are held by institutions such as insurance companies. The book value of Amedisys was presently reported as 34.62. The company has Price/Earnings To Growth (PEG) ratio of 1.25. Amedisys had not issued any dividends in recent years. The entity had 4:3 split on the 5th of December 2006. Amedisys, Inc., together with its subsidiaries, provides healthcare services in the United States. Amedisys, Inc. was incorporated in 1982 and is headquartered in Baton Rouge, Louisiana. Amedisys operates under Medical Care Facilities classification in the United States and is traded on NASDAQ Exchange. It employs 21000 people. For more info on Amedisys please contact Richard Ashworth at 225 292 2031 or go to https://www.amedisys.com.

Amedisys Quarterly Total Revenue

598.05 Million

Amedisys Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Amedisys' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Amedisys or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Over 91.0% of the company shares are held by institutions such as insurance companies
Latest headline from MacroaxisInsider: Acquisition by Nick Muscato of 5832 shares of Amedisys subject to Rule 16b-3

Amedisys Upcoming and Recent Events

21st of February 2024
Upcoming Quarterly Report
View
1st of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
21st of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

Amedisys Largest EPS Surprises

Earnings surprises can significantly impact Amedisys' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2003-05-13
2003-03-310.080.090.0112 
2002-11-11
2002-09-300.080.10.0225 
2014-05-08
2014-03-31-0.04-0.07-0.0375 
View All Earnings Estimates

Amedisys Environmental, Social, and Governance (ESG) Scores

Amedisys' ESG score is a quantitative measure that evaluates Amedisys' performance and commitment regarding environmental, social, and governance (ESG) factors. These scores are becoming increasingly crucial in investment decision-making processes, providing insights into non-financial aspects of Amedisys' operations that may have significant financial implications and affect Amedisys' stock price as well as guide investors towards more socially responsible investments.

Amedisys Stock Institutional Investors

Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Shares
Alliancebernstein L.p.2024-12-31
677.8 K
Magnetar Financial Llc2024-12-31
637.4 K
Water Island Capital Llc2024-12-31
603.6 K
Geode Capital Management, Llc2024-12-31
573 K
Pacer Advisors, Inc.2024-12-31
558.2 K
Qube Research & Technologies2024-12-31
511.6 K
Dimensional Fund Advisors, Inc.2024-12-31
503.4 K
Calamos Advisors Llc2024-12-31
487.4 K
Cnh Partners, Llc2024-12-31
472 K
Vanguard Group Inc2024-12-31
3.2 M
Blackrock Inc2024-12-31
3.2 M
Note, although Amedisys' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Amedisys Market Capitalization

The company currently falls under 'Mid-Cap' category with a current market capitalization of 3.03 B.

Amedisys Profitablity

The company has Profit Margin (PM) of 0.02 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.08 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.08.
Last ReportedProjected for Next Year
Return On Tangible Assets 0.05  0.06 
Return On Capital Employed 0.06  0.06 
Return On Assets 0.02  0.01 
Return On Equity 0.04  0.04 

Management Efficiency

Amedisys has return on total asset (ROA) of 0.0624 % which means that it generated a profit of $0.0624 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.0332 %, meaning that it created $0.0332 on every $100 dollars invested by stockholders. Amedisys' management efficiency ratios could be used to measure how well Amedisys manages its routine affairs as well as how well it operates its assets and liabilities. At present, Amedisys' Return On Capital Employed is projected to increase slightly based on the last few years of reporting. The current year's Return On Equity is expected to grow to 0.04, whereas Return On Assets are forecasted to decline to 0.01. At present, Amedisys' Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Non Currrent Assets Other is expected to grow to about 92.4 M, whereas Net Tangible Assets are projected to grow to (288.1 M).
Last ReportedProjected for Next Year
Book Value Per Share 36.06  37.87 
Tangible Book Value Per Share(3.52)(3.34)
Enterprise Value Over EBITDA 42.58  24.66 
Price Book Value Ratio 2.62  2.55 
Enterprise Value Multiple 42.58  24.66 
Price Fair Value 2.62  2.55 
Enterprise Value8.8 B9.2 B
Amedisys benefits from a proactive management team that anticipates market trends. Our analysis delves into how this proactive stance influences financial metrics and stock valuation.
Operating Margin
0.0772
Profit Margin
0.0184
Beta
0.764
Return On Assets
0.0624
Return On Equity
0.0332

Technical Drivers

As of the 20th of March, Amedisys shows the mean deviation of 0.3531, and Risk Adjusted Performance of 0.1464. Amedisys technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Please confirm Amedisys downside deviation, treynor ratio, expected short fall, as well as the relationship between the variance and potential upside to decide if Amedisys is priced correctly, providing market reflects its regular price of 92.89 per share. Given that Amedisys has jensen alpha of 0.1153, we suggest you to validate Amedisys's prevailing market performance to make sure the company can sustain itself at a future point.

Amedisys Price Movement Analysis

Execute Study
The output start index for this execution was nineteen with a total number of output elements of fourty-two. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Amedisys middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Amedisys. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.

Amedisys Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Amedisys insiders, such as employees or executives, is commonly permitted as long as it does not rely on Amedisys' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Amedisys insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Amedisys Outstanding Bonds

Amedisys issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Amedisys uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Amedisys bonds can be classified according to their maturity, which is the date when Amedisys has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.

Amedisys Predictive Daily Indicators

Amedisys intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Amedisys stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Amedisys Corporate Filings

F4
6th of March 2025
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
ViewVerify
10K
28th of February 2025
An amendment to a previously filed Form 10-K
ViewVerify
10K
27th of February 2025
Annual report required by the U.S. Securities and Exchange Commission (SEC) of a company financial performance
ViewVerify
8K
26th of February 2025
Report filed with the SEC to announce major events that shareholders should know about
ViewVerify
F4
24th of February 2025
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
ViewVerify
F4
19th of February 2025
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
ViewVerify
8K
8th of January 2025
Report filed with the SEC to announce major events that shareholders should know about
ViewVerify
8K
3rd of January 2025
Report filed with the SEC to announce major events that shareholders should know about
ViewVerify

Amedisys Forecast Models

Amedisys' time-series forecasting models are one of many Amedisys' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Amedisys' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

About Amedisys Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Amedisys prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Amedisys shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Amedisys. By using and applying Amedisys Stock analysis, traders can create a robust methodology for identifying Amedisys entry and exit points for their positions.
Last ReportedProjected for Next Year
Pretax Profit Margin 0.04  0.04 
Operating Profit Margin 0.04  0.04 
Net Profit Margin 0.02  0.02 
Gross Profit Margin 0.43  0.52 

Current Amedisys Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Amedisys analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Amedisys analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
96.86Hold10Odds
Amedisys current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Amedisys analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Amedisys stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Amedisys, talking to its executives and customers, or listening to Amedisys conference calls.
Amedisys Analyst Advice Details

Amedisys Stock Analysis Indicators

Amedisys stock analysis indicators help investors evaluate how Amedisys stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Amedisys shares will generate the highest return on investment. By understating and applying Amedisys stock analysis, traders can identify Amedisys position entry and exit signals to maximize returns.
Begin Period Cash Flow138.9 M
Long Term Debt339.3 M
Common Stock Shares Outstanding33.1 M
Total Stockholder Equity1.1 B
Tax Provision48.1 M
Quarterly Earnings Growth Y O Y-0.354
Property Plant And Equipment Net123.6 M
Cash And Short Term Investments303.2 M
Cash303.2 M
Accounts Payable40 M
Net Debt156.9 M
50 Day M A92.1072
Total Current Liabilities514.4 M
Other Operating Expenses2.3 B
Non Current Assets Total1.5 B
Forward Price Earnings18.7266
Non Currrent Assets Other88 M
Stock Based Compensation30.6 M

Complementary Tools for Amedisys Stock analysis

When running Amedisys' price analysis, check to measure Amedisys' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Amedisys is operating at the current time. Most of Amedisys' value examination focuses on studying past and present price action to predict the probability of Amedisys' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Amedisys' price. Additionally, you may evaluate how the addition of Amedisys to your portfolios can decrease your overall portfolio volatility.
Top Crypto Exchanges
Search and analyze digital assets across top global cryptocurrency exchanges
Transaction History
View history of all your transactions and understand their impact on performance
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Equity Valuation
Check real value of public entities based on technical and fundamental data
Commodity Channel
Use Commodity Channel Index to analyze current equity momentum
Portfolio Dashboard
Portfolio dashboard that provides centralized access to all your investments
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.